Supreme Pharmaceuticals Inc (FIRE), the Materials sector company, has received a rating update from a Wall Street analyst on May 14. Analyst Robert Fagan from GMP FirstEnergy reiterated a Buy rating, with a C$2.75 price target on May 14.
Fagan has an average return of 3.3% when recommending Supreme Pharmaceuticals Inc.
According to TipRanks.com, Fagan is ranked #772 out of 5183 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Supreme Pharmaceuticals Inc with a C$2.50 average price target.
Based on Supreme Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$7.14 million. In comparison, last year the company had a GAAP net loss of C$3.37 million.
The Supreme Cannabis Co., Inc. engages in the production and sale of medical cannabis. It also cultivates and distributes sun-grown cannabis through its wholly-owned subsidiary 7ACRES. The company was founded by John Fowler on June 12, 1979 and is headquartered in Toronto, Canada.
The company’s shares closed on Thursday at C$1.87.
